Global Immune Thrombocytopenia Treatment Market Insights and Forecast to 2031

Report ID: 1751040 | Published Date: Jan 2025 | No. of Page: 111 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Corticosteroids
        1.2.3 Intravenous Immunoglobulin (IVIG)
        1.2.4 Anti-D Immunoglobulin
        1.2.5 Thrombopoietin Receptor Agonist (TPO-RA)
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals and Clinics
        1.3.3 Research and Academic Institutes
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Immune Thrombocytopenia Treatment Market Perspective (2017-2028)
    2.2 Immune Thrombocytopenia Treatment Growth Trends by Region
        2.2.1 Immune Thrombocytopenia Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Immune Thrombocytopenia Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Immune Thrombocytopenia Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Immune Thrombocytopenia Treatment Market Dynamics
        2.3.1 Immune Thrombocytopenia Treatment Industry Trends
        2.3.2 Immune Thrombocytopenia Treatment Market Drivers
        2.3.3 Immune Thrombocytopenia Treatment Market Challenges
        2.3.4 Immune Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue
        3.1.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue (2017-2022)
        3.1.2 Global Immune Thrombocytopenia Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Immune Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Immune Thrombocytopenia Treatment Revenue
    3.4 Global Immune Thrombocytopenia Treatment Market Concentration Ratio
        3.4.1 Global Immune Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Treatment Revenue in 2021
    3.5 Immune Thrombocytopenia Treatment Key Players Head office and Area Served
    3.6 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
    3.7 Date of Enter into Immune Thrombocytopenia Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenia Treatment Breakdown Data by Type
    4.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2017-2022)
    4.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2023-2028)
5 Immune Thrombocytopenia Treatment Breakdown Data by Application
    5.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2017-2022)
    5.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Immune Thrombocytopenia Treatment Market Size (2017-2028)
    6.2 North America Immune Thrombocytopenia Treatment Market Size by Type
        6.2.1 North America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
        6.2.2 North America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
        6.2.3 North America Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    6.3 North America Immune Thrombocytopenia Treatment Market Size by Application
        6.3.1 North America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
        6.3.2 North America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
        6.3.3 North America Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    6.4 North America Immune Thrombocytopenia Treatment Market Size by Country
        6.4.1 North America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
        6.4.2 North America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Immune Thrombocytopenia Treatment Market Size (2017-2028)
    7.2 Europe Immune Thrombocytopenia Treatment Market Size by Type
        7.2.1 Europe Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
        7.2.2 Europe Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
        7.2.3 Europe Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    7.3 Europe Immune Thrombocytopenia Treatment Market Size by Application
        7.3.1 Europe Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
        7.3.2 Europe Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
        7.3.3 Europe Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    7.4 Europe Immune Thrombocytopenia Treatment Market Size by Country
        7.4.1 Europe Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type
        8.2.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    8.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application
        8.3.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    8.4 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region
        8.4.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Immune Thrombocytopenia Treatment Market Size (2017-2028)
    9.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type
        9.2.1 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
        9.2.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
        9.2.3 Latin America Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    9.3 Latin America Immune Thrombocytopenia Treatment Market Size by Application
        9.3.1 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
        9.3.2 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
        9.3.3 Latin America Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    9.4 Latin America Immune Thrombocytopenia Treatment Market Size by Country
        9.4.1 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type
        10.2.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    10.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application
        10.3.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    10.4 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country
        10.4.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 CSL Behring
        11.1.1 CSL Behring Company Details
        11.1.2 CSL Behring Business Overview
        11.1.3 CSL Behring Immune Thrombocytopenia Treatment Introduction
        11.1.4 CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.1.5 CSL Behring Recent Developments
    11.2 Amgen
        11.2.1 Amgen Company Details
        11.2.2 Amgen Business Overview
        11.2.3 Amgen Immune Thrombocytopenia Treatment Introduction
        11.2.4 Amgen Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.2.5 Amgen Recent Developments
    11.3 F.Hoffmann-La Roche
        11.3.1 F.Hoffmann-La Roche Company Details
        11.3.2 F.Hoffmann-La Roche Business Overview
        11.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Introduction
        11.3.4 F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.3.5 F.Hoffmann-La Roche Recent Developments
    11.4 Kyowa Hakko Kirin
        11.4.1 Kyowa Hakko Kirin Company Details
        11.4.2 Kyowa Hakko Kirin Business Overview
        11.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Introduction
        11.4.4 Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.4.5 Kyowa Hakko Kirin Recent Developments
    11.5 Rigel Pharmaceuticals
        11.5.1 Rigel Pharmaceuticals Company Details
        11.5.2 Rigel Pharmaceuticals Business Overview
        11.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
        11.5.4 Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.5.5 Rigel Pharmaceuticals Recent Developments
    11.6 Shionogi
        11.6.1 Shionogi Company Details
        11.6.2 Shionogi Business Overview
        11.6.3 Shionogi Immune Thrombocytopenia Treatment Introduction
        11.6.4 Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.6.5 Shionogi Recent Developments
    11.7 Dova Pharmaceuticals
        11.7.1 Dova Pharmaceuticals Company Details
        11.7.2 Dova Pharmaceuticals Business Overview
        11.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
        11.7.4 Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.7.5 Dova Pharmaceuticals Recent Developments
    11.8 Novartis
        11.8.1 Novartis Company Details
        11.8.2 Novartis Business Overview
        11.8.3 Novartis Immune Thrombocytopenia Treatment Introduction
        11.8.4 Novartis Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.8.5 Novartis Recent Developments
    11.9 Shire
        11.9.1 Shire Company Details
        11.9.2 Shire Business Overview
        11.9.3 Shire Immune Thrombocytopenia Treatment Introduction
        11.9.4 Shire Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.9.5 Shire Recent Developments
    11.10 Ligand Pharmaceuticals
        11.10.1 Ligand Pharmaceuticals Company Details
        11.10.2 Ligand Pharmaceuticals Business Overview
        11.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
        11.10.4 Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.10.5 Ligand Pharmaceuticals Recent Developments
    11.11 GSK
        11.11.1 GSK Company Details
        11.11.2 GSK Business Overview
        11.11.3 GSK Immune Thrombocytopenia Treatment Introduction
        11.11.4 GSK Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.11.5 GSK Recent Developments
    11.12 Grifols Biologicals
        11.12.1 Grifols Biologicals Company Details
        11.12.2 Grifols Biologicals Business Overview
        11.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Introduction
        11.12.4 Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.12.5 Grifols Biologicals Recent Developments
    11.13 Jiangsu Hengrui Pharmaceutical
        11.13.1 Jiangsu Hengrui Pharmaceutical Company Details
        11.13.2 Jiangsu Hengrui Pharmaceutical Business Overview
        11.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Introduction
        11.13.4 Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2017-2022)
        11.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
List of Tables
    Table 1. Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Corticosteroids
    Table 3. Key Players of Intravenous Immunoglobulin (IVIG)
    Table 4. Key Players of Anti-D Immunoglobulin
    Table 5. Key Players of Thrombopoietin Receptor Agonist (TPO-RA)
    Table 6. Key Players of Others
    Table 7. Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Immune Thrombocytopenia Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Immune Thrombocytopenia Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Immune Thrombocytopenia Treatment Market Share by Region (2017-2022)
    Table 11. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Immune Thrombocytopenia Treatment Market Share by Region (2023-2028)
    Table 13. Immune Thrombocytopenia Treatment Market Trends
    Table 14. Immune Thrombocytopenia Treatment Market Drivers
    Table 15. Immune Thrombocytopenia Treatment Market Challenges
    Table 16. Immune Thrombocytopenia Treatment Market Restraints
    Table 17. Global Immune Thrombocytopenia Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Immune Thrombocytopenia Treatment Revenue Share by Players (2017-2022)
    Table 19. Global Top Immune Thrombocytopenia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2021)
    Table 20. Ranking of Global Top Immune Thrombocytopenia Treatment Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Immune Thrombocytopenia Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Immune Thrombocytopenia Treatment Product Solution and Service
    Table 24. Date of Enter into Immune Thrombocytopenia Treatment Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2017-2022)
    Table 28. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2023-2028)
    Table 30. Global Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Immune Thrombocytopenia Treatment Revenue Share by Application (2017-2022)
    Table 32. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Immune Thrombocytopenia Treatment Revenue Share by Application (2023-2028)
    Table 34. North America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Immune Thrombocytopenia Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Immune Thrombocytopenia Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 64. CSL Behring Company Details
    Table 65. CSL Behring Business Overview
    Table 66. CSL Behring Immune Thrombocytopenia Treatment Product
    Table 67. CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 68. CSL Behring Recent Developments
    Table 69. Amgen Company Details
    Table 70. Amgen Business Overview
    Table 71. Amgen Immune Thrombocytopenia Treatment Product
    Table 72. Amgen Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 73. Amgen Recent Developments
    Table 74. F.Hoffmann-La Roche Company Details
    Table 75. F.Hoffmann-La Roche Business Overview
    Table 76. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product
    Table 77. F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 78. F.Hoffmann-La Roche Recent Developments
    Table 79. Kyowa Hakko Kirin Company Details
    Table 80. Kyowa Hakko Kirin Business Overview
    Table 81. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product
    Table 82. Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 83. Kyowa Hakko Kirin Recent Developments
    Table 84. Rigel Pharmaceuticals Company Details
    Table 85. Rigel Pharmaceuticals Business Overview
    Table 86. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 87. Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 88. Rigel Pharmaceuticals Recent Developments
    Table 89. Shionogi Company Details
    Table 90. Shionogi Business Overview
    Table 91. Shionogi Immune Thrombocytopenia Treatment Product
    Table 92. Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 93. Shionogi Recent Developments
    Table 94. Dova Pharmaceuticals Company Details
    Table 95. Dova Pharmaceuticals Business Overview
    Table 96. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 97. Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 98. Dova Pharmaceuticals Recent Developments
    Table 99. Novartis Company Details
    Table 100. Novartis Business Overview
    Table 101. Novartis Immune Thrombocytopenia Treatment Product
    Table 102. Novartis Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 103. Novartis Recent Developments
    Table 104. Shire Company Details
    Table 105. Shire Business Overview
    Table 106. Shire Immune Thrombocytopenia Treatment Product
    Table 107. Shire Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 108. Shire Recent Developments
    Table 109. Ligand Pharmaceuticals Company Details
    Table 110. Ligand Pharmaceuticals Business Overview
    Table 111. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 112. Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 113. Ligand Pharmaceuticals Recent Developments
    Table 114. GSK Company Details
    Table 115. GSK Business Overview
    Table 116. GSK Immune Thrombocytopenia Treatment Product
    Table 117. GSK Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 118. GSK Recent Developments
    Table 119. Grifols Biologicals Company Details
    Table 120. Grifols Biologicals Business Overview
    Table 121. Grifols Biologicals Immune Thrombocytopenia Treatment Product
    Table 122. Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 123. Grifols Biologicals Recent Developments
    Table 124. Jiangsu Hengrui Pharmaceutical Company Details
    Table 125. Jiangsu Hengrui Pharmaceutical Business Overview
    Table 126. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product
    Table 127. Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 128. Jiangsu Hengrui Pharmaceutical Recent Developments
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Immune Thrombocytopenia Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Corticosteroids Features
    Figure 3. Intravenous Immunoglobulin (IVIG) Features
    Figure 4. Anti-D Immunoglobulin Features
    Figure 5. Thrombopoietin Receptor Agonist (TPO-RA) Features
    Figure 6. Others Features
    Figure 7. Global Immune Thrombocytopenia Treatment Market Share by Application: 2021 VS 2028
    Figure 8. Hospitals and Clinics Case Studies
    Figure 9. Research and Academic Institutes Case Studies
    Figure 10. Others Case Studies
    Figure 11. Immune Thrombocytopenia Treatment Report Years Considered
    Figure 12. Global Immune Thrombocytopenia Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Immune Thrombocytopenia Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Immune Thrombocytopenia Treatment Market Share by Region: 2021 VS 2028
    Figure 15. Global Immune Thrombocytopenia Treatment Market Share by Players in 2021
    Figure 16. Global Top Immune Thrombocytopenia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Immune Thrombocytopenia Treatment Revenue in 2021
    Figure 18. North America Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 19. North America Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
    Figure 20. North America Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
    Figure 21. North America Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
    Figure 22. United States Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Canada Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. Europe Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
    Figure 26. Europe Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
    Figure 27. Europe Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
    Figure 28. Germany Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. France Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. U.K. Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Italy Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Russia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Nordic Countries Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Immune Thrombocytopenia Treatment Market Size Share by Region (2017-2028)
    Figure 38. China Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Japan Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. South Korea Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Southeast Asia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. India Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Australia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 44. Latin America Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 45. Latin America Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
    Figure 46. Latin America Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
    Figure 47. Latin America Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
    Figure 48. Mexico Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Brazil Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Immune Thrombocytopenia Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Market Share by Type (2017-2028)
    Figure 52. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Market Share by Application (2017-2028)
    Figure 53. Middle East and Africa Immune Thrombocytopenia Treatment Market Size Share by Country (2017-2028)
    Figure 54. Turkey Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. UAE Immune Thrombocytopenia Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. CSL Behring Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 58. Amgen Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 59. F.Hoffmann-La Roche Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 60. Kyowa Hakko Kirin Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 61. Rigel Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 62. Shionogi Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 63. Dova Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 64. Novartis Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 65. Shire Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 66. Ligand Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 67. GSK Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 68. Grifols Biologicals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 69. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Frequently Asked Questions
Immune Thrombocytopenia Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Immune Thrombocytopenia Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Immune Thrombocytopenia Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Automatic Windows

Automatic Windows market is segmented by Type and by Application. Players, stakeholders, and othe ... Read More